Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2023—LGC SeraCare has developed three contrived, tumor normal cell-line–derived homologous recombinant deficiency reference materials: Seraseq FFPE HRD High-Positive RM, Seraseq FFPE HRD Low-Positive RM, and Seraseq FFPE HRD Negative RM.
March 2023—PerkinElmer debuted its Zephyr G3 NGS iQ workstation at the Society for Laboratory Automation and Screening conference in San Diego, Feb. 25–March 1. The system enables the automated construction of up to 96 NGS libraries and is composed of a high-performing liquid handler, integrated thermocycler, robotic arm, and deck accessories and peripherals. The workstation is available with an optional cloud-based software to further simplify creating and editing NGS protocols, the company says, by using a single pane of glass interface and developing methods from scientific intent rather than code.
March 2023—Bio-Rad launched its CFX Opus Deepwell Dx real-time PCR system, an open platform for developing in vitro diagnostic assays. The system multiplexes up to five targets and allows reaction volumes up to 125 µL in a 96-well format for quantitative PCR diagnostic assays. CFX Maestro Dx SE software provides data management and analysis tools.
January 2023—General Data Healthcare launched its LaserTrack Flex cassette printer. The Flex has a footprint of 13” L × 19” W and a capacity that starts at 480 cassettes, with each magazine holding 80 cassettes; it can be upgraded to hold up to 800 cassettes. The standard configuration prints on the face of the cassette and can be upgraded to also print on one or both sides. Cassettes can be loaded on the right or left side of the printer.
January 2023—Roche has launched its Anti-PRAME (EPR20330) Rabbit Monoclonal Primary Antibody to identify PRAME protein expression in tissue samples from patients who are suspected of having melanoma. Studies suggest that the detection of PRAME expression by immunohistochemistry complements findings from routinely used tests and enables more informed clinical decisions and improved patient outcomes, according to a company press release.
January 2023—BioMérieux announced the CE marking of its Vidas Kube, a next-generation automated immunoassay system for the company’s Vidas range. The system features a stackable and modular benchtop design and is compatible with the existing routine test menu covering emergency and critical care, immunochemistry, and infectious diseases. The commercial launch is planned in selected countries at the beginning of the year, extending gradually to the rest of the world during the second quarter.
January 2023—EKF Diagnostics’ DiaSpect handheld hemoglobin analyzer now connects securely to EKF Link, the company’s point-of-care middleware. DiaSpect is also now equipped with Bluetooth and internal storage for 4,000 tests and QC results, as well as the capability to provide a calculated hematocrit value alongside the hemoglobin result. Test results are stored and accessed securely on a centralized platform.
January 2023—Santé Consulting and Vanguard Healthcare Staffing announced a partnership in which the companies will provide recruiting support for anatomic and clinical laboratories.
January 2023—LGC SeraCare announced the availability of its Seraseq FFPE BRCA1/2 LGR Reference Material intended for use with next-generation sequencing assays or amplified nucleic-acid–based methods that identify somatic and germline variants in BRCA1 and BRCA2 genes. The reference material contains 20 DNA variants in the genomic background of GM24385. One 10-μm formalin-fixed, paraffin-embedded curl is provided per vial.
January 2023—Bio-Rad Laboratories has announced that Exact Diagnostics HBV, HCV, and HIV-1 screen controls are available in Europe. The controls are designed to monitor the performance of blood donor screening assays and are calibrated against the Third WHO International Standard for HBV (NIBSC code 10/264) and HIV-1 (10/152) and the Fourth WHO International Standard for HCV (06/102). The products are made of whole viruses in a citrate plasma matrix to ensure lot-to-lot reproducibility, have an 18-month shelf life from date of manufacture when stored at −20°C or below, and are stable for 24 hours when stored at 2° to 8°C.
